Фороза

Quick links to important sections

Фороза

Selected form

Treatment option: Osteoporosis, Hip Fracture

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Фороза

Фороза: Quick Facts and Definitional Overview

Property Description
Active ingredient Alendronic Acid (as Alendronate Sodium)
Pharmacological Class Nitrogen-containing Bisphosphonate (N-BP)
Form Oral Tablet, Soluble/Effervescent Tablet, Oral Solution
General Purpose Bone density conservation
Origin Synthetic analog of Pyrophosphate

Фороза: A Nitrogen-Containing Bisphosphonate for Bone Density

Фороза (Forosa) is a prescription-only pharmaceutical product whose active ingredient is Alendronic Acid (INN), supplied as Alendronate Sodium. Alendronic Acid belongs to the pharmacological group of bisphosphonates, specifically a potent Nitrogen-containing Bisphosphonate (N-BP). This classification means the medicine is chemically synthesized to interfere with skeletal processes, a function clinically recognized for its role in long-term bone management.

As a single-component product (monotherapy), Фороза is designated for the oral route (Per Os) of administration and is notably available in several dosage forms, including the standard Oral Tablet and the soluble/effervescent tablet. This variety in form is a differentiating feature, offering an alternative to the standard tablet which can aid patients who must adhere to the strict administration protocols common to all oral bisphosphonates. The compound itself is a synthetic analog of pyrophosphate, a natural substance integral to bone metabolism.


What is the General Purpose of Alendronic Acid?

The main general purpose of Alendronic Acid is to serve as a bone density conservation agent by significantly preserving existing skeletal structure. Its physiological action centers on the inhibition of osteoclastic bone resorption, which is the biological process responsible for the body's removal of old bone tissue. Alendronic Acid is utilized for its role in treating conditions where bone weakening is a concern.

This action involves the active compound binding directly to the mineral surface of the bone, thereby targeting and reducing the activity of osteoclasts. By impeding the work of these removal cells and slowing the rate of overall bone turnover, the medication supports the structural integrity and strength of the skeletal framework. Consequently, the primary benefit of the drug is maintaining or increasing bone mineral density over time in target patient groups.

Regulatory References

  1. WHO Essential Medicines Lists
  2. Alendronic Acid (WHO EML)

What side effects are possible with Фороза?

Possible Side Effects and Safety Information

The safety profile for Фороза (Alendronate Sodium) is structured around adverse reaction classifications defined in official regulatory documents (such as the FDA and EMA). These classifications detail which organ systems are affected and the typical frequency of reported events.

Musculoskeletal pain, affecting bone, muscle, or joint, is the most frequently reported adverse reaction, classified as Very Common (occurring in ge 1/10 patients). Common adverse reactions (occurring in ge 1/100 to <1/10 patients) primarily involve Gastrointestinal Disorders, including abdominal pain, dyspepsia, constipation, and esophageal irritation.

Rare but serious adverse reactions are also officially documented. These include Osteonecrosis of the Jaw (ONJ) and Atypical Subtrochanteric and Diaphyseal Femoral Fractures, both of which are generally associated with long-term exposure. Severe upper GI events, such as esophageal ulcers, erosions, and stricture, have been reported, as have severe skin reactions like Stevens-Johnson syndrome.

Safety limitations explicitly stated in labeling include restrictions for patients with certain esophageal abnormalities or those unable to remain upright after administration. The medication is not recommended for individuals with severe renal impairment (creatinine clearance less than 35 mL/min). Furthermore, pre-existing hypocalcemia must be corrected prior to initiating therapy, as a transient, asymptomatic decrease in serum calcium may occur, particularly at the beginning of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe the potential manifestations and required emergency actions for an overdose of Фороза (Alendronic Acid), focusing on both local injury and systemic effects.


Documented Overdose Profile

Overdose scope Regulatory-Documented Details
Documented Manifestations Upset stomach, heartburn, esophagitis, and gastritis (gastrointestinal injury); Hypocalcemia (low serum calcium levels) and Hypophosphatemia (low serum phosphate levels).
Serious Outcomes Potential for severe upper gastrointestinal injury, including ulceration and the rare risk of esophageal perforation or bleeding.
Antidote Information No specific antidote is known for Alendronic Acid overdose.

Required Emergency Actions

Immediate medical attention is required upon suspected overdose or the development of symptoms indicative of severe esophageal irritation, such as pain on swallowing (odynophagia), retrosternal pain, or new/worsening heartburn.

In case of overdose, the regulatory guidance states that milk or antacids should be administered to bind the excess drug and reduce further absorption and local injury. Vomiting should not be induced due to the risk of exacerbating esophageal damage. Treatment is entirely supportive, focusing on managing the clinical symptoms and correcting metabolic imbalances, such as administering intravenous calcium for clinically severe hypocalcemia.

Therapeutic Uses of Фороза

Main Uses and Therapeutic Indications

Фороза belongs to a group of non-hormonal medicines known as bisphosphonates. Its primary function is to inhibit the loss of bone mass by regulating the activity of cells that break down bone tissue. This medication is typically prescribed for the management of bone-related conditions characterized by decreased density and increased fragility.

Treatment of Osteoporosis in Postmenopausal Women

The most common application of this medication is for the treatment of osteoporosis in women following menopause. During this period, hormonal changes can lead to a more rapid loss of bone density, making bones thinner and more brittle. The medication helps to increase bone mineral density and reduce the risk of vertebral and hip fractures.

Treatment of Osteoporosis in Men

While less common than in women, men can also develop osteoporosis due to aging or specific medical factors. Фороза is used to strengthen the skeletal structure in men, aiming to prevent bone loss and lower the probability of fractures.

Benefits and Mechanism of Action

Bone Density Preservation

The active component works by binding to the mineral surfaces of the bone. It specifically targets osteoclasts—the cells responsible for bone resorption. By slowing down the rate at which these cells remove bone tissue, the medication allows the body's bone-building cells to maintain or improve the overall density of the skeleton.

Fracture Risk Reduction

The primary clinical benefit of this treatment is the significant reduction in the risk of bone injuries. This includes:

  • Vertebral Fractures: Strengthening the bones of the spine to prevent compression fractures.
  • Hip Fractures: Protecting one of the most critical areas prone to injury in patients with low bone density.
  • Non-vertebral Fractures: Improving the general resilience of other bones, such as the wrist or ribs.

Long-term Skeletal Health

By normalizing the bone turnover cycle, the medication helps to stabilize the architectural integrity of the bone over time. This process is essential for patients whose natural bone remodeling balance has been disrupted, helping to maintain an active lifestyle by decreasing the likelihood of debilitating bone injuries.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Фороза (Furosemide) — Official Regulatory Information

Furosemide is generally used to treat edema in adults and pediatric patients associated with congestive heart failure, liver cirrhosis, or kidney disease, including nephrotic syndrome.


Populations for whom use is Contraindicated

Regulatory documents explicitly prohibit the use of this medicine in patients with:

  • Anuria (inability to pass urine).
  • Hypersensitivity (severe allergic reaction) to furosemide or any of its components, which may include cross-sensitivity to sulfonamide-derived drugs.
  • Severe hypovolaemia or dehydration.
  • Severe hypokalaemia (low potassium) or severe hyponatraemia (low sodium).
  • Hepatic coma and pre-comatose states associated with liver disease.
  • Breast-feeding women (as per some regulatory agencies).

Special Considerations and Restrictions

Use requires careful monitoring and may be restricted in specific groups:

Population / Condition Eligibility Constraint
Elderly Patients Higher risk of dehydration, vascular thrombosis, and embolism; requires cautious, gradual dosing.
Pediatric Patients Premature infants may be at increased risk of kidney issues (nephrocalcinosis/nephrolithiasis).
Severe Renal Disease Should be discontinued if increasing azotemia and oliguria occur. Anuria not responsive to treatment is a contraindication.
Urinary Outflow Obstruction Requires careful monitoring due to the risk of acute urinary retention (e.g., enlarged prostate).
Pregnancy Use requires a discussion of risks versus benefits; fetal growth should be monitored.

Furosemide is a potent diuretic that must be used under close medical supervision due to the risk of profound water and electrolyte depletion, which defines its core safety constraint regarding eligible patients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Фороза (Alendronic Acid) has a defined interaction profile centered on its high susceptibility to absorption interference and pharmacodynamic additive effects, as documented by regulatory authorities.

Pharmacokinetic Interactions (Absorption)

Co-administration with oral products containing multivalent cations significantly reduces the bioavailability of Alendronic Acid. Substances that interfere with absorption include calcium supplements, antacids, and other oral medications containing minerals (such as iron or magnesium). These products must be administered at least 30 minutes after Alendronic Acid to ensure adequate absorption. Furthermore, consumption of all food and all beverages other than plain water (including coffee and juices) must also follow the same 30-minute separation rule, as their simultaneous presence results in negligible drug absorption.

Pharmacodynamic Interactions

The simultaneous use of Alendronic Acid with aspirin or other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) is officially noted to worsen upper gastrointestinal irritation, requiring caution. While Alendronic Acid is not metabolized in the body, which precludes typical CYP-mediated interactions, co-administration with intravenous ranitidine has been shown to double its oral bioavailability, although the clinical significance remains unknown. Use in patients with a Glomerular Filtration Rate (GFR) less than 35 mL/min is not recommended due to limited data regarding drug clearance.

Mechanism of Action

Selective Binding and Osteoclast Targeting

The pharmacological action of Фороза (Alendronic Acid) begins with the drug's high chemical affinity for hydroxyapatite, the mineral structure of bone. This mechanism allows the compound to selectively concentrate at active sites of bone remodeling, ensuring it is preferentially internalized by the osteoclast cells responsible for resorption.

Inhibition of the Mevalonate Pathway

Once inside the osteoclast, the compound acts as a competitive inhibitor of the enzyme Farnesyl Pyrophosphate Synthase (FPPS) within the Mevalonate pathway. This blockage prevents the production of essential isoprenoid lipids, resulting in the non-prenylation of small GTPases required for the cell's cytoskeletal organization.

Induction of Cellular Apoptosis

The functional disruption caused by FPPS inhibition results in the rapid apoptosis (programmed cell death) of the osteoclast. This targeted reduction in the active osteoclast population lowers the rate of skeletal turnover, with the physiological consequence being a net suppression of bone resorption.

Dosage and Administration Information

How Фороза Is Used: Administration Guidelines

Фороза (Alendronic Acid) is prescribed for oral administration and is available in multiple strengths, including 5 mg, 10 mg, 35 mg, 40 mg, and 70 mg tablets, as well as a 70 mg oral solution or effervescent tablet.

Standard Dosing and Frequency

Administration patterns are defined by the specific condition being addressed. The regimens include once-daily options, such as 10 mg for osteoporosis treatment or 40 mg daily for a six-month course in Paget’s disease of bone. Alternatively, a once-weekly regimen, typically 70 mg, is used for osteoporosis treatment.

If a weekly dose is missed, instructions specify taking it the morning after the oversight, but never two doses on the same day; the patient should then resume the original weekly schedule.

Administration Conditions and Constraints

To ensure proper absorption and administration, specific procedural steps must be followed:

  • Timing: The medicine must be taken at least 30 minutes before any food, beverage (other than plain water), or any other medication of the day.
  • Liquid: The tablet must be swallowed whole with a full glass of plain water (approximately 200 mL).
  • Posture: To facilitate passage, the patient must remain sitting or standing upright for a minimum of 30 minutes after dosing and until after consuming the first food of the day.
  • Tablet Integrity: Tablets must be swallowed whole and should not be crushed, chewed, or allowed to dissolve in the mouth.

Population-Specific Use

Dosage adjustments are generally not required for older adults or patients with mild to moderate hepatic or renal impairment. However, Фороза use is not recommended for individuals with severe renal impairment (Creatinine Clearance < 35 mL/min), and it is not recommended for pediatric use. Furthermore, for long-term use, the need for continued therapy should be re-evaluated periodically, with consideration for discontinuation after 3 to 5 years for low-risk patients.

Recent Clinical Evidence

Research evidence / Overview of studies for Фороза

Evidence for Use in Postmenopausal Osteoporosis

Research exploring Alendronic Acid in postmenopausal women primarily involves large, randomized, controlled clinical trials (RCTs) lasting three to four years. These studies measured specific endpoints, including changes in Bone Mineral Density (BMD) at the hip and spine, and the observed rates of new clinical fractures. Comparisons were made against a placebo. Studies tracked and measured BMD changes, reporting patterns consistent with preservation or increase in the treated group. Research reported a pattern of lower observed rates of new vertebral and hip fractures. The evidence level for this indication is graded as high due to the volume and design of the pivotal trials, though findings related to other non-vertebral fracture sites were reported as variable.


Evidence for Use in Osteoporosis in Men

Research examining this medicine in men with osteoporosis has historically involved smaller, shorter Randomized Controlled Trials (RCTs). The evidence level for this indication is commonly described as moderate. These studies monitored changes in BMD at the lumbar spine and hip, with the incidence of new vertebral fractures also being tracked. The available data show patterns related to skeletal measures, where studies tracked and reported a measured change in BMD relative to the control group. A key research limitation is that primary trials in men were often powered to detect changes in BMD rather than non-vertebral fracture endpoints, meaning follow-up durations were limited.


Evidence for Other Approved Bone Conditions

Research has also explored the compound's use in Glucocorticoid-Induced Osteoporosis (GIOP) in men and women receiving long-term steroid therapy. Studies monitored BMD and fracture occurrence over approximately one year, with reports showing measurements consistent with maintained or increased BMD. For Paget's Disease of Bone, short-term trials (typically six months) were evaluated, focusing mainly on changes in biochemical indices of bone turnover, where findings consistently described a pattern of change in these elevated markers.


Durability and Long-Term Follow-up Data

Extension studies have tracked cohorts of postmenopausal women for up to 10 years in total to explore durability. Research highlights that changes measured during the initial treatment period were tracked for some time after the medicine was stopped. Research exploring outcomes after discontinuation reported that BMD measurements described a moderate, gradual decline when treatment was stopped after five years. The research base includes limitations: long-term effects beyond the observation of specific research cohorts are not fully established, and comparative evidence is lacking for certain head-to-head outcomes against newer therapies.

Key Studies & References

  1. Alendronate in the treatment of Paget's disease of bone (Review of 6-month RCTs)

Frequently Asked Questions (FAQ)

Common questions about Фороза (FAQ)


Q: How does Forosa work in the body, explained simply?

The active ingredient in Forosa works by binding directly to the mineral structure of your bone. This allows it to target and slow down the activity of osteoclasts, which are the natural cells responsible for breaking down old bone tissue.

By inhibiting these cells, the medication helps to slow down the process of bone loss, with the physiological consequence described in official documents being a net suppression of bone resorption, which supports the preservation or increase of bone mineral density.


Q: What contraindications are listed for Forosa in the instructions?

Official regulatory documents list several conditions where the use of Forosa is prohibited. These include a known hypersensitivity (severe allergic reaction) to any component of the drug, certain abnormalities of the esophagus, or low calcium levels (hypocalcemia) that have not been corrected.

Additionally, the medicine is contraindicated for individuals with severe kidney impairment or those who are unable to remain sitting or standing upright for at least 30 minutes after taking the dose.


Q: Why do some people not feel the effect of Forosa immediately?

Forosa is designed to create structural change within the skeletal framework, and its therapeutic action on bone density and fracture risk occurs gradually over time. Because the drug works internally on bone cells, it does not produce an immediate, noticeable subjective feeling or relief like certain medications.


Q: Does the effectiveness of Forosa decrease over time if taken long-term?

Official studies tracking the use of Forosa do not report a loss of efficacy (effectiveness) while the medication is being taken continuously. However, official information does state that the need for continued therapy should be regularly reassessed by a healthcare professional, typically after three to five years of use.


Q: Is it necessary to follow a special diet when taking Forosa?

No, a special, long-term diet is not required while using this medication. The official instructions emphasize a strict requirement to take the tablet with a full glass of plain water at least 30 minutes before consuming any food, beverages (other than water), or other medications.

This timing constraint is necessary to minimize interference with drug absorption, as co-administration with food and non-plain water beverages results in negligible drug absorption.


Q: Why does Forosa have a specific list of contraindications?

The specific restrictions listed for Forosa are primarily related to two core safety risks. The first is the risk of serious irritation to the upper gastrointestinal (GI) tract, which is why it is contraindicated in patients with certain esophageal conditions.

The second is to ensure the medicine can be safely and effectively cleared from the body, leading to restrictions for those with severe kidney impairment.


Q: Is it true that Forosa can cause an allergic reaction?

Yes, regulatory safety information confirms that hypersensitivity (allergic reactions) has been officially reported. These reactions can manifest as a skin rash, hives, or a severe swelling known as angioedema.


Q: Are there specific symptoms that may indicate intolerance to Forosa?

Official recommendations define intolerance to this class of medication as a persistent and sufficiently severe disturbance in the upper gastrointestinal (GI) tract that may warrant discontinuation of treatment.

GI issues associated with this class of drug often include abdominal pain, dyspepsia (indigestion), or constipation.


Q: What does it mean that Forosa 'requires caution' in certain chronic conditions?

When official documents state that the drug 'requires caution' for certain chronic conditions (such as specific gastrointestinal issues or vitamin deficiencies), it means the medicine can be used, but the patient must be carefully monitored.

The treatment involves a higher level of medical oversight and a thorough risk-benefit assessment by a doctor.


Q: Why is it important to check the full list of Forosa interactions with other drugs?

Checking the list of interactions is important because the co-administration of certain substances, like calcium supplements, antacids, or even food, can significantly reduce the absorption of Forosa, potentially rendering the treatment ineffective.

Other interactions, such as with NSAIDs (Nonsteroidal Anti-Inflammatory Drugs), can increase the risk of adverse effects like upper gastrointestinal irritation.


Q: What do official instructions say about taking Forosa during pregnancy or breastfeeding?

Official regulatory documentation explicitly states that the use of Forosa is contraindicated during both pregnancy and breastfeeding.


How should Фороза be stored and disposed of?

How to Store and Dispose of Фороза

Storage of Фороза (alendronate sodium) must adhere strictly to documented regulatory requirements to ensure product integrity and safety.

Required Storage Conditions

  • Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
  • Protection: The medicine must be protected from moisture.
  • Container: Keep the tablets in the tightly closed container in which they were originally dispensed.

Child Safety and Disposal

  • Child Safety: The medication must be stored out of the sight and reach of children to prevent accidental exposure.
  • Disposal: Discard all expired medicines. Unused product and waste material must be disposed of in accordance with local requirements or by consulting a healthcare professional for guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Фороза found in:

A-Z Index: